Pomegra
Swiss biotech Nouscom closed an oversubscribed €120M Series D co-led by M Ventures and Revelation Partners for its Lynch syndrome cancer-prevention trial.
Key Takeaways
- Nouscom raised €120M ($135M) in an oversubscribed Series D on October 19, 2026.
- M Ventures and Revelation Partners co-led. Angelini Industries, the European Investment Bank and Neva SGR joined as new investors.
- Proceeds fund one global registration-enabling trial of NOUS-209, which holds FDA Fast Track designation.
Lead
Nouscom, a Basel-based clinical-stage biotech, announced on October 19, 2026 that it closed a €120 million ($135 million) Series D financing. M Ventures and Revelation Partners co-led the round. The money will pay for a single global, registration-enabling trial of NOUS-209, an off-the-shelf neoantigen immunotherapy designed to stop cancer in people with Lynch syndrome before tumors form. The company did not disclose a valuation.
Who Invested in the Round?
The round added three new backers: Angelini Industries, investing through Angelini Investments, the European Investment Bank through its Aurea facility, and Neva SGR, part of the Intesa Sanpaolo Group. Every existing investor took part. That group includes 5AM Ventures, Andera Partners, Angelini Ventures, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, XGEN Ventures, Bpifrance and CDP Venture Capital.
Full insider participation after an extended Series C, which reached €75.8 million by March 2024, suggests existing holders were satisfied with the data. The €120 million figure is also about 60% larger than that Series C. The oversubscription is the company's own description, and the amount turned away was not disclosed. The EIB's presence points to public-sector appetite for European late-stage biotech financing, which has been thin outside the largest rounds.
What Is NOUS-209 and How Does It Work?
NOUS-209 is a viral-vector vaccine that targets shared frameshift neoantigens. These are abnormal protein fragments produced by tumors with mismatch repair deficiency, the defect at the core of Lynch syndrome. Because the same neoantigens recur across carriers, one product can serve many patients. That separates it from the individualized mRNA cancer vaccines in development at Merck & Co. and Moderna, which must be manufactured for each patient.
Lynch syndrome is a hereditary condition affecting roughly 1 in 300 people, or about 2 million carriers. It raises lifetime cancer risk to as much as 80%. Colorectal cancer risk reaches up to 50%, against about 2% in the general population. Most carriers are undiagnosed. Current management relies on frequent colonoscopies and surgery.
What Does the Clinical Data Show?
In the Phase 1b/2 study, all evaluable carriers dosed with NOUS-209 stayed free of advanced adenomas and colorectal cancer at colonoscopy follow-up. The year-one assessment covered 43 carriers and the year-two assessment covered 17. Of 45 healthy carriers dosed, 37 were evaluated for immune response. All 37 showed neoantigen-specific responses, and 85% still had them after one year. The results were published in Science Translational Medicine. Eduardo Vilar-Sanchez is the principal investigator.
The sample is small, and the study had no control arm. Single-arm numbers in a population where cancer develops over years carry limited weight, which is why a registration-enabling design matters more than the early signal. The FDA's Fast Track designation allows more frequent agency contact and rolling review, but it does not change the approval standard. The company will present longer-term follow-up at the ESMO congress in Madrid in late October 2026.
Why Does the Trial Design Matter for Prevention?
The trial design matters because prevention endpoints are slow and expensive to prove. A drug that stops cancer in healthy people must show it prevents advanced adenomas or tumors over years, in an otherwise screened population. Regulators have limited precedent for cancer-interception products. Nouscom has said the €120 million is meant to fund one global trial rather than several, a tight budget for a study of this type. The company has not published enrollment targets, endpoints or readout timing in the material reviewed.
Nouscom also runs Phase 2 studies combining NOUS-209 with pembrolizumab in advanced dMMR/MSI-H metastatic colorectal cancer, a separate and more conventional oncology path.
Leadership and Strategic Context
CEO Marina Udier has led Nouscom since an interim appointment in May 2019 that later became permanent. Her background includes Novartis, McKinsey and Versant Ventures. The company was founded by Riccardo Cortese, who died in 2017. Udier said the financing "puts us closer to a world where cancer is stopped before it starts."
Other European developers raising in the same period include mbiomics, with a €30 million Series A in April 2026, and TILT Biotherapeutics, with $25.6 million in May 2025. Nouscom's round is several times larger than either.
Outlook
Nouscom now has funding for a pivotal Lynch syndrome trial, backing from a broad European investor base and a regulatory designation that speeds agency dialogue. The ESMO data in late October will show whether the early prevention signal holds over a longer follow-up. Trial size, endpoints and timelines remain undisclosed, and the evidence will be tested in a controlled setting rather than an open-label one.
